Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BLCM - Bellicum Pharmaceuticals Inc


Previous close
0.461
0   0%

Share volume: 26,934
Last Updated: Mon 07 Aug 2023 06:00:00 AM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$0.46
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
43%
Profitability 54%
Dept financing 20%
Liquidity 21%
Performance 45%
Company vs Stock growth
vs
Performance
5 Days
7.21%
1 Month
36.59%
3 Months
53.67%
6 Months
53.67%
1 Year
53.67%
2 Year
53.67%
Key data
Stock price
$0.46
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.15 - $0.52
52 WEEK CHANGE
$0.54
MARKET CAP 
4.378 M
YIELD 
N/A
SHARES OUTSTANDING 
9.496 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,676
AVERAGE 30 VOLUME 
$41,616
Company detail
CEO: Richard Fair
Region: US
Website: http://www.bellicum.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

Recent news